<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520738</url>
  </required_header>
  <id_info>
    <org_study_id>17-AOIP-01</org_study_id>
    <nct_id>NCT03520738</nct_id>
  </id_info>
  <brief_title>Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis.</brief_title>
  <acronym>PIPAL</acronym>
  <official_title>Arterial Calcifications: Role of Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis. PIPAL Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular calcification is a common finding in chronic kidney disease and increases arterial
      stiffness leading to augmented cardiovascular morbidity. The calcification process is
      thoroughly regulated by pro and anticalcifying agents. The investigators hypothesize that
      imbalance in these compounds could depend on alkaline phosphatase activity. Therefore, the
      investigators will measure ALP activity, calcifications score, arterial stiffness and perform
      a bio-collection in monogenic rare diseases characterized by various levels of anticalcifying
      agents and in diverse CKD stages characterized by various levels of procalcifying compounds.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) describes the gradual loss of kidney function from stage 1
      (normal renal function) to stage 5 requiring maintenance dialysis or kidney transplantation
      (KT). Vascular calcification in CKD is a common finding and increases arterial stiffness
      leading to increased cardiovascular morbidity. The calcification process is the same for
      bones and arteries and is thoroughly regulated by pro and anticalcifying agents. Actually,
      inorganic phosphates (Pi) accelerate the calcification process and their levels are found
      increased in advanced CKD stage. In contrast, inorganic pyrophosphates (PPi) are potent
      anti-calcifying compounds resulting from the hydrolysis of extracellular ATP, but their role
      in CKD remains elusive. Tissue-nonspecific alkaline phosphatases (TNAP) convert PPi into Pi
      in calcification sites leading to hydroxyapatite deposition. The metabolism of PPi depends on
      diverse compounds, which are included in our bio-collection (Favre, Int J Mol Sci, 2017). The
      activity of plasma Alkaline Phosphatase (ALP) reflects the tissue production of TNAP. ALP
      activity is correlated to cardiovascular events in CKD patients. Preliminary results from our
      group show a stable plasma level of the PPi/Pi ratio independently from the glomerular
      filtration rate.

      The investigators hypothesize that PPi/Pi imbalance could depend on ALP activity and could be
      a key determinant of vascular calcifications and arterial stiffness.

      Therefore, the investigators will measure ALP activity, calcifications score, arterial
      stiffness and perform a bio-collection in monogenic rare diseases and in various CKD stages
      including hyperphosphatemic patients on maintenance hemodialysis.

      Stage 1 and 2 CKD patients will be considered as a reference group because Pi levels and PPi
      levels are usually normal and calcification level is low. These patients will be compared to
      CKD patients with various Pi levels : low Pi levels in KT recipients 6 weeks after graft and
      high Pi levels in patients on maintenance dialysis. These patients (CKD 1 and 2) will be
      compared to patients with various PPi levels: patients with pseudoxanthoma elasticum (PXE)
      with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with
      high PPi levels and bone decalcification. PXE and HPP are rare monogenic disorder resulting
      from mutation in ABCC6 and the gene encoding TNAP respectively.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALP activity (alkaline phosphatase activity)</measure>
    <time_frame>at time = day 0 (inclusion)</time_frame>
    <description>ALP activity will be plotted against the PPi/Pi ratio in CKD patients with various Pi levels; a regression curve will be used to measure the correlation between these two factors</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood and urinary samples on the following patients:
10 Stage 1 and 2 CKD patients 10 patients 6 weeks after graft 10 patients on maintenance dialysis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudoxanthoma elasticum (PXE)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood and urinary samples on the following patients:
10 patients with pseudoxanthoma elasticum (PXE) with low PPi levels and vascular calcifications and patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypophosphatasia (HPP)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood and urinary samples on the following patients:
4 patients with hypophosphatasia (HPP) with high PPi levels and bone decalcification.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>Blood samples on an empty stomach</description>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_label>Pseudoxanthoma elasticum (PXE)</arm_group_label>
    <arm_group_label>Hypophosphatasia (HPP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Urinary samples</intervention_name>
    <description>first urinary in the morning</description>
    <arm_group_label>Chronic Kidney Disease</arm_group_label>
    <arm_group_label>Pseudoxanthoma elasticum (PXE)</arm_group_label>
    <arm_group_label>Hypophosphatasia (HPP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with Chronic kidney disease (stage 1 or 2, 6 weeks after graft or patients on
             maintenance dialysis) or patient with pseudoxanthoma elasticum or patient with
             hypophosphatasia

          -  informed consent signed

        Exclusion Criteria:

          -  cancer

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume FAVRE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology Department, Nice University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume FAVRE, MD</last_name>
    <phone>0492038428</phone>
    <email>favre.g@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU d'Angers - Service de Dermatologie</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>MARTIN Ludovic, Pr</last_name>
      <email>LuMartin@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>MARTIN Ludovic, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de MÃ©decine Vacsulaire - CHU d'ANGERS</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samir HENNI, Dr</last_name>
      <email>Samir.henni@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Samir HENNI, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume FAVRE, Dr</last_name>
      <phone>4 92 03 88 24</phone>
      <phone_ext>+33</phone_ext>
      <email>favre.g@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Guillaume FAVRE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence CHALMIN, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>VÃ©ronique BREUIL, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laetitia ALBANO, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandor VIDO, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent ESNAULT, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georges LEFTHERIOTIS, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Rhumatologie - HÃ´pital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian ROUX, Pr</last_name>
      <email>Christian.roux@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christian ROUX, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

